Lung Combo Panel II - IHC (ALK D5F3, ROS1, PDL1, c-MET) & RT-PCR (EGFR [Hot Spot] exons 18, 19, 20, 21) near me in Chennai

Lung cancer can be treated more effectively by targeting specific genetic changes in the tumor. Key genes like EGFR, ALK, ROS1, BRAF, MET, and PD-L1 offer potential targets for personalized therapy. Mutations in EGFR and gene fusions in ALK and ROS1 can be treated with targeted drugs. Other mutations, like BRAF and MET alterations, also guide treatment decisions. Additionally, PD-L1 expression helps clinicians to determine if immunotherapy drugs might be effective.

This test is a combo test to detect ALK, ROS1, PDL1, and cMET status by IHC and EGFR mutational status by RT PCR to help determine the best treatment options for lung cancer patients.

Disclaimer:

In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.